$2.70
0.02[0.75%]
At close: Apr 24
$2.70
0[0.00%]
After Hours: 4:05PM EDT
Nuvation Bio
(NYSE:NUVB)Nuvation Bio Stock (NYSE:NUVB), Analyst Ratings, Price Targets, Predictions
Nuvation Bio Inc has a consensus price target of $5.79, established from looking at the 19 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, HC Wainwright & Co., and Jefferies on April 17, 2024, March 28, 2024, and March 27, 2024. With an average price target of $7.67 between RBC Capital, HC Wainwright & Co., and Jefferies, there's an implied 183.95% upside for Nuvation Bio Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
HC Wainwright & Co.
Jefferies
BTIG
Wedbush
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Nuvation Bio
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/17/2024 | NUVB | Buy Now | Nuvation Bio | $2.70 | 85.19% | RBC Capital | Kennen MacKay | $4 → $5 | Maintains | Outperform | Get Alert |
| 03/28/2024 | NUVB | Buy Now | Nuvation Bio | $2.70 | 196.3% | HC Wainwright & Co. | Robert Burns | $5 → $8 | Maintains | Buy | Get Alert |
| 03/27/2024 | NUVB | Buy Now | Nuvation Bio | $2.70 | 270.37% | Jefferies | Michael Yee | $1.4 → $10 | Upgrade | Hold → Buy | Get Alert |
| 03/26/2024 | NUVB | Buy Now | Nuvation Bio | $2.70 | 85.19% | BTIG | Kaveri Pohlman | → $5 | Upgrade | Neutral → Buy | Get Alert |
| 03/07/2024 | NUVB | Buy Now | Nuvation Bio | $2.70 | 85.19% | HC Wainwright & Co. | Robert Burns | $4.5 → $5 | Maintains | Buy | Get Alert |
| 03/01/2024 | NUVB | Buy Now | Nuvation Bio | $2.70 | 85.19% | Wedbush | David Nierengarten | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 11/22/2023 | NUVB | Buy Now | Nuvation Bio | $2.70 | 66.67% | HC Wainwright & Co. | Robert Burns | → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2023 | NUVB | Buy Now | Nuvation Bio | $2.70 | 66.67% | HC Wainwright & Co. | Robert Burns | → $4.5 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | NUVB | Buy Now | Nuvation Bio | $2.70 | 85.19% | RBC Capital | Gregory Renza | $6 → $5 | Maintains | Outperform | Get Alert |
| 03/24/2023 | NUVB | Buy Now | Nuvation Bio | $2.70 | 66.67% | HC Wainwright & Co. | Robert Burns | → $4.5 | Reiterates | → Buy | Get Alert |
| 03/16/2023 | NUVB | Buy Now | Nuvation Bio | $2.70 | 85.19% | Wedbush | David Nierengarten | → $5 | Reiterates | → Outperform | Get Alert |
| 03/16/2023 | NUVB | Buy Now | Nuvation Bio | $2.70 | 122.22% | RBC Capital | Gregory Renza | → $6 | Reiterates | → Outperform | Get Alert |
| 01/06/2023 | NUVB | Buy Now | Nuvation Bio | $2.70 | -25.93% | Jefferies | Michael Yee | $5 → $2 | Downgrade | Buy → Hold | Get Alert |
| 08/22/2022 | NUVB | Buy Now | Nuvation Bio | $2.70 | 66.67% | HC Wainwright & Co. | Robert Burns | $14 → $4.5 | Maintains | Buy | Get Alert |
| 08/02/2022 | NUVB | Buy Now | Nuvation Bio | $2.70 | -7.41% | BMO Capital | Evan Seigerman | $8 → $2.5 | Downgrade | Outperform → Market Perform | Get Alert |
| 08/02/2022 | NUVB | Buy Now | Nuvation Bio | $2.70 | — | BTIG | Kaveri Pohlman | — | Downgrade | Buy → Neutral | Get Alert |
| 05/11/2022 | NUVB | Buy Now | Nuvation Bio | $2.70 | 418.52% | RBC Capital | Gregory Renza | $15 → $14 | Maintains | Outperform | Get Alert |
| 05/04/2022 | NUVB | Buy Now | Nuvation Bio | $2.70 | 418.52% | HC Wainwright & Co. | Robert Burns | → $14 | Initiates | → Buy | Get Alert |
| 03/22/2022 | NUVB | Buy Now | Nuvation Bio | $2.70 | 344.44% | BMO Capital | Evan Seigerman | $17 → $12 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Nuvation Bio (NUVB)?
The latest price target for Nuvation Bio (NYSE: NUVB) was reported by RBC Capital on April 17, 2024. The analyst firm set a price target for $5.00 expecting NUVB to rise to within 12 months (a possible 85.19% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Nuvation Bio (NUVB)?
The latest analyst rating for Nuvation Bio (NYSE: NUVB) was provided by RBC Capital, and Nuvation Bio maintained their outperform rating.
When was the last upgrade for Nuvation Bio (NUVB)?
The last upgrade for Nuvation Bio Inc happened on March 27, 2024 when Jefferies raised their price target to $10. Jefferies previously had a hold for Nuvation Bio Inc.
When was the last downgrade for Nuvation Bio (NUVB)?
The last downgrade for Nuvation Bio Inc happened on January 6, 2023 when Jefferies changed their price target from $5 to $2 for Nuvation Bio Inc.
When is the next analyst rating going to be posted or updated for Nuvation Bio (NUVB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nuvation Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nuvation Bio was filed on April 17, 2024 so you should expect the next rating to be made available sometime around April 17, 2025.
Is the Analyst Rating Nuvation Bio (NUVB) correct?
While ratings are subjective and will change, the latest Nuvation Bio (NUVB) rating was a maintained with a price target of $4.00 to $5.00. The current price Nuvation Bio (NUVB) is trading at is $2.70, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.